Morgan Stanley reiterates Olaplex stock rating on weak guidance By Investing.com

Olaplex guided fiscal 2026 implied EBITDA of $86.9M–$95.7M (below $97.3M consensus) and EBITDA margin of 21%–22% (vs 22.5% consensus). Q4 adjusted EBITDA beat at $12.9M (consensus $10M) and EPS was $0.01 (vs $0.0047 forecast) while revenue was roughly $105.1M (slightly below $105.68M); gross margin remains high near 71–72%. Morgan Stanley reiterated Equalweight with a $1.40 target while lowering FY26/27 EBITDA estimates ~2% and Evercore cut its target from $4.00 to $2.50; shares have dropped ~15% over the past week to $1.30 (market cap ~$857M).

Analysis

Olaplex’s profile — a high gross-margin consumer brand facing a near-term topline visibility gap — creates a classic operating-leverage mismatch: its unit economics can absorb price competition, but any shift toward higher promotional intensity or elevated marketing spend will flow disproportionately to EBITDA. That makes current moves driven by guidance risk rather than permanent impairment; the market is pricing optionality on demand stabilization rather than underlying product margin durability.

A key second-order risk is channel mix rebalancing. If wholesale partners push for deeper trade discounts or slower reorder cadence to clear inventory, Olaplex will see margin slippage even without a consumer demand collapse. Conversely, a re-acceleration through direct-to-consumer or premium salon channels would restore margin upside but requires sustained marketing investment and time to convert.

Time horizons differ: expect volatility over days-to-weeks around analyst revisions and retailer sell-through reads, but the real inflection will take quarters as new distribution/marketing strategies either restore unit economics or dilute them. Event triggers to watch are twofold — wholesale inventory reports and management commentary on customer-acquisition-cost trends — any improvement would materially reduce downside risk.

Opportunity cost matters: capital allocated to this name is exposed to binary guidance outcomes, so a reallocation into higher-momentum, lower-guidance-sensitivity names in the portfolio (where implied upside is clearer) is a pragmatic alternative while waiting for a clearer demand signal.

Key Decisions for Investors

• Initiate a tactical 3–6 month put-spread on OLPX (buy 6M ATM puts, sell 6M OTM puts ~25–35% below) sized at 3–5% portfolio notional to cap worst-case drawdown while keeping asymmetric downside exposure; target >2:1 downside/reported-premium if guidance misses persist.
• Establish a pair trade: short OLPX equity (notional 1x) vs long SMCI equity (notional 1x) for 1–3 month tactical rotation — rationale: shift from guidance-sensitive consumer beta to momentum/earnings-reward tech upside; stop-loss on pair if relative performance reverses by 8–10%.
• If conviction on longer-term brand resilience, scale a small, staged long in OLPX (avg cost in tranches over 3 quarters) funded by the above reallocation; require sequential topline prints or concrete channel-restocking commentary before adding beyond initial tranche.
• Rotate freed capital into dispersion convexity: buy long-dated APP calls (12–18 months) sized to provide upside participation in higher-growth, ad-driven revenue recovery — expect asymmetric payoff if macro ad budgets normalize, cap allocation at 2–4% portfolio.